Therapeutic Multispecific Antibody Development Services
A further increase in antibody specificity of multi-specific antibodies may yield higher efficacy compared to mono-specific and bispecific antibodies. Alfa Cytology offers development services for therapeutic multi-specific antibodies in different combinations to advance the development of novel cancer therapies.
Introduction to Multi-specific Antibody
Multi-specific antibodies enhance antibody-mediated effects. For example, they have the potential to target multiple rather than one tumor-associated antigen (TAA) due to a greater number of antigen-binding regions and can further recruit and activate immune cells more strongly. In most designs, they have at least one of three specificities for binding to T or NK cells and at least one targeting tumor-associated antigen. The functional enhancement of therapeutic multi-specific antibodies has important implications.
Higher Response Rate
The higher response rate of multi-specific antibodies is attributed to their ability to engage multiple targets simultaneously, resulting in enhanced binding and activation of immune cells and increased the likelihood of effective targeting and elimination of disease cells.
Less Drug Resistance
Multi-specific antibodies are less prone to drug resistance because they target multiple pathways, making it difficult for the disease to develop resistance against all targets simultaneously. Additionally, they can overcome single-target mutations by simultaneously binding to different targets.
Simpler Development Process
The simpler development process of multi-specific antibodies is due to their ability to simultaneously target multiple antigens. It simplifies the drug development process compared to the complex, expensive, and time-consuming procedures required to launch multiple monospecific products.
Our Services
Because the use of multi-specific antibodies as single therapeutic agents can achieve better therapeutic effects than combinations of different monoclonal antibodies, a great deal of effort has been put into developing multi-specific antibodies. Alfa Cytology helps our customers to develop therapeutic multi-specific antibodies that open new avenues to address the complex biology of cancer and the onset of anti-tumor immune responses.
- Multi-specific Antibodies Designing Services
Multimerization of different building blocks can change the size, shape, and valence of antibodies to optimize half-life and tumor penetration. Our company offers development services for therapeutic multi-specific antibodies in IgG-like form with Fc (Fragment crystallizable) region and non-IgG-like form without Fc region. The smaller size of the non-IgG-like form compared to traditional IgG enhances tumor penetration at the expense of faster clearance.
- Multiple Mechanisms for Cancer Therapy
Immune cell engagers (ICE) are molecules capable of redirecting immune effector cells against cancer cells with the aim of triggering effective tumor cell damage, acting as a bridge between immune cells and target cells. The combination of different binding portions in a single multi-specific antibody molecule offers a variety of new therapeutic options. In addition to targeting multiple receptors in tumor cells, we can help customers enhance immune cell activation by adding ICE to multi-specific antibodies, such as T-cell engagers (TCE) and NK-cell engagers (NKCE).
- One-stop Therapeutic Antibody Development
Alfa Cytology provides a one-stop solution for multi-specific antibodies for cancer therapy, including antigen development services, antibody discovery services, antibody optimization and engineering services, and antibody characterization services.
Workflow of Therapeutic Multispecific Antibody Development
Target Identification
Identifying potential target molecules that are involved in the disease pathway through genomics and proteomics.
01
Target Validation
The identified targets are further validated to ensure their relevance and suitability as therapeutic targets.
02
Antibody Generation
Generation of specific anti-cancer antibodies using hybridoma technology, phage display, and transgenic animals.
03
Lead Antibody Selection
Functional assays and engineering techniques are applied to optimize their therapeutic potential.
04
Preclinical Studies
Efficacy, safety, pharmacokinetics, and pharmacodynamics are tested in relevant disease models.
05
Multi-specific antibodies are expanding the toolbox of anti-tumor reagents as they improve the ability to target the multifactorial nature of cancer. Alfa Cytology provides services for the design, expression, and functional characterization of multi-specific antibodies. Please contact us for more information.
For research use only.
Related Services
